Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives

A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and an active ingredient of the general formula I:

• R2 is C1-C6 alkyl unsubstituted or substituted by a radical selected from the group consisting of —SO3H, C1-C6 alkoxy, phenyl, 4-(C1-C6)alkylphenyl, 4-(C1-C6)alkoxyphenyl, 2-furyl, tetrahydro-2-furyl, or 1,3-benzodioxinyl, or R2 is cycloalkyl or C2-C6 alkenyl;
• R3 is phenyl substituted by at least one radical selected from the group consisting of C1-C6 alkyl, hydroxy(C1-C6)alkyl, C1-C6 alkoxy, cyano, halogen, trifluoromethyl, cycloalkyl, aralkyl, aryl, substituted aryl, and heterocyclyl;
• R4 and R5 each is hydrogen or C1-C6 alkyl;
• R6 and R7 each is selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted by piperidinyl, 4-morpholinyl, piperazinyl, 4-(C1-C6)alkyl-piperazinyl, 4-arylpiperazinyl, 4-aralkylpiperazinyl, or imidazolyl;
• C3-C7 cycloalkyl, C6-C10 aryl, and C7-C16 aralkyl, or R3 and R4 together with the nitrogen atom to which they are attached form a 5 to 7 membered saturated heterocyclic ring containing one or two heteroatoms, or such 5 to 7 membered saturated heterocyclic ring containing an additional nitrogen atom substituted by C1-C6 alkyl or C1-C6 alkyl substituted by a radical selected from the group consisting of halogen, hydroxyl, C1-C6 alkoxy and phenyl, or by C2-C7 alkoxycarbonyl, and pharmaceutically acceptable salts thereof.